Search research articles
Contact Us
Filters
Showing results (81-90 of 112) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
Angela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Scientific Reports
|
November 20, 2019
Elemental Zn and its Binding Protein Zinc-α2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Kate Poropatich, Tatjana Paunesku, Alia Zander, et al.
The Lancet. Oncology
|
January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Varun Monga, Scott Okuno, Brian Van Tine, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
Mark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 112) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
Angela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Scientific Reports
|
November 20, 2019
Elemental Zn and its Binding Protein Zinc-α2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Kate Poropatich, Tatjana Paunesku, Alia Zander, et al.
The Lancet. Oncology
|
January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Varun Monga, Scott Okuno, Brian Van Tine, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
Mark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Page
of 12